Cetuximab: Adverse Event Profile and Recommendations for Toxicity Management

Melodie Thomas, BSN, RN, OCN®, CCRP

The epidermal growth factor receptor (EGFR, c-ErbB-1, HER-1) is a member of the HER family of receptors, which includes HER-2, a receptor targeted in breast cancer therapy (Baselga, 2002). The EGFR is expressed in many human tumors, including colorectal (Messa, Russo, Caruso, & Di Leo, 1998; Salomon, Brandt, Ciardiello, & Normanno, 1995), bladder, brain, cervical, esophageal, pancreatic, kidney, ovarian, and breast cancers, with a generally favorable toxicity profile; the maximum tolerated dose has not been defined (Bos et al., 1996; Falcey et al., 1997). Partial responses and stable disease were reported in more than one-third of the patients with irinotecan-refractory colorectal cancer included in a recently reported trial (Saltz et al., 2004). In a randomized, phase II trial of irinotecan-refractory, metastatic colorectal cancer, patients treated with single-agent cetuximab achieved partial responses in 10.8% of cases, and the disease control rate was 32.4%; patients receiving cetuximab plus irinotecan exhibited partial response and overall disease control rates of 22.9% and 55.5%, respectively; and median times to tumor progression in each arm were 1.5 months.

Cetuximab (Erbitux™, IMC-C225, ImClone Systems Incorporated, New York, NY) is a monoclonal antibody targeted to the epidermal growth factor receptor. Expression of the epidermal growth factor receptor is associated with disease progression, poor survival, poor response to therapy, and the development of resistance to therapy in many solid tumors. Cetuximab blocks the binding of natural ligands to the epidermal growth factor receptor, thus inhibiting oncogetic processes associated with its activation. Infusion reactions, acneform skin rash, and nail disorder are the most clinically relevant adverse events observed. Because infusion reactions can be life threatening when severe, nurses must administer prophylactic treatment with an H1 antagonist prior to infusion and actively manage cetuximab-related infusion reactions when they occur. Management of infusion reactions typically includes vigilant patient monitoring, appropriate medical supervision, readily available resources for the treatment of infusion reactions, and initiation of institution- or practice-specific protocols when necessary. Acneform skin rash is the most common adverse event, but severe (grade 3 or 4) rash requiring interruption of treatment is not common. Topical and systemic antibiotic therapies may be administered to reduce symptoms. Nail disorder typically is mild to moderate and is observed infrequently; this also may be treated with systemic and topical antibiotics. Overall, the safety profile of cetuximab is favorable compared to that typically seen with chemotherapeutic agents. The acneform skin rash and nail disorder, which may affect quality of life, rarely threaten the general well-being of patients and typically are manageable.

Clinical trials have shown that cetuximab has activity against many tumor types, including head and neck, prostate, lung, esophageal, pancreatic, kidney, ovarian, and breast cancers, with a generally favorable toxicity profile; the maximum tolerated dose has not been defined (Bos et al., 1996; Falcey et al., 1997). Partial responses and stable disease were reported in more than one-third of the patients with irinotecan-refractory colorectal cancer included in a recently reported trial (Saltz et al., 2004). In a randomized, phase II trial of irinotecan-refractory, metastatic colorectal cancer, patients treated with single-agent cetuximab achieved partial responses in 10.8% of cases, and the disease control rate was 32.4%; patients receiving cetuximab plus irinotecan exhibited partial response and overall disease control rates of 22.9% and 55.5%, respectively; and median times to tumor progression in each arm were 1.5 months.

Submitted April 2004. Accepted for publication January 5, 2005. The author received compensation from the Bristol-Myers Squibb Oncology Advisory Board for manuscript completion and served on the advisory board and speakers bureau for Bristol-Myers Squibb Oncology. The author received assistance in writing this article from Clinical Insights, Inc. (Mention of specific products and opinions related to those products do not indicate or imply endorsement by the Clinical Journal of Oncology Nursing or the Oncology Nursing Society.)

Digital Object Identifier: 10.1188/05.CJON.332-338